Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Disappointed’ UCB And Amgen Will Appeal CHMP’s Negative Evenity Decision

Executive Summary

The EMA’s CHMP cited concerns over cardiovascular side effects as the reason why it took a negative stance on Evenity’s use in the EU for treating severe osteoporosis.

You may also be interested in...



UCB Spotlights Bimekizumab And Other Later-Stage R&D Projects

Belgium-headquartered UCB has a group of antibody-based products in mid to late-stage clinical studies which will be competing in the dermatology/immune disorders marketplace in the next few years. 

Amgen's Murdo Gordon On Generating Sales Growth In A Challenging Commercial Year

Newer products are gaining ground, but not fast enough to replace sales as blockbuster products face competition. Scrip spoke with the company's global commercial head about the strategy going forward.

Romosozumab Among Latest Drugs Up For CHMP Opinion

Four drugs are up for an opinion this week on whether they should be granted EU-wide approval, including Amgen/UCB's osteoporosis drug romosozumab.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125470

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel